Other Clinical Trial - Phase 2 Study to Evaluate PVX-410 + Pembrolizumab +

See also
Status	Clinical Trial	Phase
Completed	`NCT03106415` - Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer	Phase 1/Phase 2
Suspended	`NCT05673200` - Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer	Phase 1
Active, not recruiting	`NCT02595905` - Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases	Phase 2
Suspended	`NCT05770531` - Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy	Phase 2
Active, not recruiting	`NCT05081492` - CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer	Phase 1
Recruiting	`NCT05318469` - Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT05539365` - Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer	Phase 2
Recruiting	`NCT04664829` - The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC	Phase 1
Active, not recruiting	`NCT04514484` - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Phase 1
Not yet recruiting	`NCT06008275` - Neratinib in Combination With Ruxolitinib in Patients With mTNBC	Early Phase 1
Withdrawn	`NCT05093387` - SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer	Phase 1
Terminated	`NCT03579472` - M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer	Phase 1
Completed	`NCT02898207` - Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer	Phase 1
Suspended	`NCT05422794` - Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer	Phase 1
Completed	`NCT03853707` - Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer	Phase 1/Phase 2
Recruiting	`NCT05269381` - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	Phase 1/Phase 2
Terminated	`NCT02706392` - Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies	Phase 1
Active, not recruiting	`NCT04345913` - Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT06434064` - Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer	Phase 2
Not yet recruiting	`NCT06324240` - Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer	Phase 1

NCT number	NCT04634747
Study type	Interventional
Source	OncoPep, Inc.
Contact
Status	Not yet recruiting
Phase	Phase 2
Start date	April 30, 2022
Completion date	April 1, 2025

Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms